Merck Executives Dump 140,000 Shares in Confidence Surge—Stock Stays Flat Amid Buzz‑Fueled Volatility
Merck insider buying shows confidence in its vaccine and oncology pipeline, suggesting solid mid‑term earnings growth amid mixed market sentiment.
3 minutes to read